Frequency of Erectile Dysfunction in Patients Receiving Pegylated Interferon and Ribavirin for the Treatment of Chronic Hepatitis C

Objective: The purpose behind this study was to determine the frequency of erectile dysfunction in patients receiving pegylated interferon and ribavirin for treatment chronic hepatitis C.
 Study Design: Prospective observational study.
 Setting: Department Gastroenterology Hepatology, Medical Unit III, Services Hospital, Lahore.
 Period: Six months from 10st July 2017 9th January 2018.
 Materials Methods: We have evaluated a total 130 through consecutive sampling technique who were admitted or visited Out-Patient-Department (OPD) with an underlying diagnosis C virus infection advise take anti viral regime (Pegylated combination therapy) HCV followed after 12 weeks 24 dysfunction.
 Results: A included. overall mean age 37.4±9.6 years. 83.07%. Among them, equal percentage at week did not (N = 76, 58.5%). While severe surprisingly more common (14.61%, N 19) than (13.07%, 17) treatment. Significant association only observed group 40 – 60 years (p <0.05).
 Conclusion: Erectile is potential side effect being treated but duration therapy affect prevalence sexual impairment although increasing age, significantly increased.